InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
RAW-Blue™ Cells | The Potency of Cowpea Mosaic Virus Particles for Cancer In Situ Vaccination I... | 2023 | Mol Pharm. | Jung E. et al. | DOI: 10.1021/acs.molpharmaceut.3c00214 |
EndotoxDetect™ - Colorimetric HEK-Blue™ LPS Detection Kit | Heterogeneity of Lipopolysaccharide as Source of Variability in Bioassays and... | 2023 | Int J Mol Sci. | Fux A.C. et al. | DOI: 10.3390/ijms24098395 |
2'3'-cGAMP | Stimulator of interferon genes (STING) expression in the enteric nervous syst... | 2023 | Neurogastroenterol Motil. | Dharshika C. et al. | DOI: 10.1111/nmo.14553 |
DMXAA | Stimulator of interferon genes (STING) expression in the enteric nervous syst... | 2023 | Neurogastroenterol Motil. | Dharshika C. et al. | DOI: 10.1111/nmo.14553 |
3'3'-cGAMP | Stimulator of interferon genes (STING) expression in the enteric nervous syst... | 2023 | Neurogastroenterol Motil. | Dharshika C. et al. | DOI: 10.1111/nmo.14553 |
IL-12 Reporter HEK 293 Cells | Human IL-35 Inhibits the Bioactivity of IL-12 and Its Interaction with IL-12Rβ2. | 2023 | Immunohorizons | Mahfooz N.S. et al. | DOI: 10.4049/immunohorizons.2300039 |
QUANTI-Blue™ | Human IL-35 Inhibits the Bioactivity of IL-12 and Its Interaction with IL-12Rβ2. | 2023 | Immunohorizons | Mahfooz N.S. et al. | DOI: 10.4049/immunohorizons.2300039 |
THP1-Dual™ Cells | Mesenchymal stromal cells and alpha-1 antitrypsin have a strong synergy in mo... | 2023 | Theranostics | Han L. et al. | DOI: 10.7150/thno.83942 |
RAW-Dual™ Cells | Mesenchymal stromal cells and alpha-1 antitrypsin have a strong synergy in mo... | 2023 | Theranostics | Han L. et al. | DOI: 10.7150/thno.83942 |
TLR4 agonist preparation - MPLA-SM | TLR4 Agonist MPLA Ameliorates Heavy-Ion Radiation Damage via Regulating DNA D... | 2023 | Radiat Res. | Liu T. et al. | DOI: 10.1667/RADE-22-00200.1 |
Puromycin | DYNLT1 promotes mitochondrial metabolism to fuel breast cancer development by... | 2023 | Mol Med. | Huang L. et al. | DOI: 10.1186/s10020-023-00663-0 |
ASC-GFP Reporter Monocytes | 1-Methylnicotinamide (1-MNA) inhibits the activation of the NLRP3 inflammasom... | 2023 | Int Immunopharmacol. | Sidor K. et al. | DOI: 10.1016/j.intimp.2023.110445 |
Normocin® - Antimicrobial Reagent | 1-Methylnicotinamide (1-MNA) inhibits the activation of the NLRP3 inflammasom... | 2023 | Int Immunopharmacol. | Sidor K. et al. | DOI: 10.1016/j.intimp.2023.110445 |
Poly(dA:dT) | 1-Methylnicotinamide (1-MNA) inhibits the activation of the NLRP3 inflammasom... | 2023 | Int Immunopharmacol. | Sidor K. et al. | DOI: 10.1016/j.intimp.2023.110445 |
LPS-PG (Lipopolysaccharide from P. gingivalis) | Glipizide Alleviates Periodontitis Pathogenicity via Inhibition of Angiogenes... | 2023 | Inflammation | Guo X. et al. | DOI: 10.1007/s10753-023-01850-1 |
Nigericin | Reduced mitochondrial calcium uptake in macrophages is a major driver of infl... | 2023 | Nat Aging | Seegren P.V. et al. | DOI: 10.1038/s43587-023-00436-8 |
LPS-EB (LPS from E. coli O111:B4) | Reduced mitochondrial calcium uptake in macrophages is a major driver of infl... | 2023 | Nat Aging | Seegren P.V. et al. | DOI: 10.1038/s43587-023-00436-8 |
TL8-506 | Human RELA dominant-negative mutations underlie type I interferonopathy with ... | 2023 | J Exp Med. | Moriya K. et al. | DOI: 10.1084/jem.20212276 |
R848 (Resiquimod) | Human RELA dominant-negative mutations underlie type I interferonopathy with ... | 2023 | J Exp Med. | Moriya K. et al. | DOI: 10.1084/jem.20212276 |
LPS-EB (LPS from E. coli O111:B4) | In vitro immune and redox response induced by cationic cellulose-based nanoma... | 2023 | Toxicol In Vitro | Tobias T. et al. | DOI: 10.1016/j.tiv.2023.105616 |